The Canadian Venture Building
82 Richmond Street East
Toronto, ON M5C 1P1
Full Time Employees:
|Ms. Alison D. Silva||CEO, Pres & Director||438.81k||N/A||N/A|
|Dr. Richard T. Ho||Chief Scientific Officer||257.85k||N/A||1963|
|Mr. Victor Hugo C.M.A., CPA||Chief Financial Officer||N/A||N/A||1970|
|Mr. Paul Papi||VP of Investor Relations||N/A||N/A||N/A|
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Cotinga Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.